K Number
K984165
Device Name
ANTI-THYROGLOBULIN EIA DIAGNOSTIC TEST KIT
Date Cleared
1999-02-02

(74 days)

Product Code
Regulation Number
866.5870
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
This assay is intended for the in-yitro measurement of specific IgG antibodies against thyroglobulin present in serum, as an aid in the diagnosis of autoimmune thyroid diseases.
Device Description
Not Found
More Information

Not Found

None

No
The summary describes an in-vitro diagnostic assay for measuring antibodies, with no mention of AI, ML, image processing, or any other technology typically associated with AI/ML in medical devices.

No
The device is described as an "assay ... for the in-vitro measurement of specific IgG antibodies..." which aids in diagnosis. It does not provide any treatment or therapy.

Yes
This device aids in the diagnosis of autoimmune thyroid diseases by measuring specific IgG antibodies.

No

The 510(k) summary describes an "assay" intended for the "in-vitro measurement" of antibodies in "serum." This strongly suggests a laboratory-based test involving physical reagents and equipment, not a software-only device. The lack of any mention of software, algorithms, or digital processing further supports this conclusion.

Based on the provided information, yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The "Intended Use / Indications for Use" explicitly states that the assay is intended for the in-vitro measurement of specific IgG antibodies against thyroglobulin present in serum. The term "in-vitro" is a key indicator of an IVD, meaning it's used to test samples taken from the body, outside of the body.
  • Purpose: The purpose is described as "as an aid in the diagnosis of autoimmune thyroid diseases." This diagnostic purpose further confirms its classification as an IVD.

While other sections like "Device Description," "Mentions image processing," "Mentions AI, DNN, or ML," etc., are listed as "Not Found," the core definition of an IVD is met by the stated intended use.

N/A

Intended Use / Indications for Use

This assay is intended for the in-yitro measurement of specific IgG antibodies against thyroglobulin present in serum, as an aid in the diagnosis of autoimmune thyroid diseases.

Product codes

JZO

Device Description

Not Found

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

Not Found

Key Metrics

Not Found

Predicate Device(s)

Not Found

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 866.5870 Thyroid autoantibody immunological test system.

(a)
Identification. A thyroid autoantibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the thyroid autoantibodies (antibodies produced against the body's own tissues). Measurement of thyroid autoantibodies may aid in the diagnosis of certain thyroid disorders, such as Hashimoto's disease (chronic lymphocytic thyroiditis), nontoxic goiter (enlargement of thyroid gland), Grave's disease (enlargement of the thyroid gland with protrusion of the eyeballs), and cancer of the thyroid.(b)
Classification. Class II (performance standards).

0

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

2 1999 FEB

The Binding Site, Limited C/O Mr. Jay H. Geller East Tower, Suite 600 2425 West Olympic Boulevard Santa Monica, California 90404

Re : K984165 Trade Name: Anti-Thyroglobulin Diagnostic Test Kit Requlatory Class: II Product Code: JZO Dated: November 19, 1998 Received: November 20, 1998

Dear Mr. Geller:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in requlatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

1

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

K984165

INDICATIONS FOR USE STATEMENT

Anti-Thyroglobulin Enzyme Immunoassay Kit Device Name:

This assay is intended for the in-yitro Indications for Use: of specific IgG antibodies against thyroglobulin measurement present in serum, as an aid in the diagnosis of autoimmune thyroid diseases.

Peter E. Madini

(Division Sign-Off) Division of Clinical Laboratory Dev 510(k) Number

Pescription

ATTACHMENT A